In a recent development, a special master in a New Jersey federal court recommended that Mylan and several pharmaceutical wholesalers be allowed to continue pursuing certain claims against Teva Pharmaceuticals. These claims involve allegations that Teva engaged in practices such as regulatory deception, false advertising, and giving improper rebates. The objective, as alleged, was to delay the introduction of generic competitors to its Copaxone treatment for multiple sclerosis. However, not all of the parallel claims will move forward, according to the recommendation.
For further details on the proceedings and the implications involved, visit the Law360 article.